Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6279955 | 0.90 | ALOX5 (0.46) | ALOX5EPHX1TRPM8LMNAADRA2A | |
| SCHEMBL7475015 | 0.83 | ALOX5 (0.55) | ALOX5EPHX1TRPM8LMNAADRA2A | |
| SCHEMBL28260719 | 0.83 | ALOX5 (0.55) | ALOX5EPHX1TRPM8LMNAADRA2A | |
| SCHEMBL2454614 | 0.82 | CYP2D6 (0.52) | ALOX5LMNAHIF1AKDM4ECYP2D6 | |
| SCHEMBL5221261 | 0.81 | DPP4 (0.50) | ALOX5EPHX1TRPM8LMNAADRA2A | |
| SCHEMBL8178447 | 0.81 | ALOX5 (0.48) | ALOX5EPHX1TRPM8LMNAADRA2A | |
| SCHEMBL8376271 | 0.81 | CYP2D6 (0.52) | ALOX5EPHX1TRPM8LMNAADRA2A | |
| SCHEMBL6689864 | 0.80 | CYP2D6 (0.44) | ALOX5LMNACYP2D6SRCMAPK1 | |
| Hydrochloric Acid SCHEMBL10371299 | 0.79 | DPP4 (0.49) | ALOX5EPHX1TRPM8LMNAADRA2A | |
| SCHEMBL3301641 | 0.79 | ALOX5 (0.47) | ALOX5EPHX1TRPM8LMNAADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108586287-A | A kind of preparation method of 2- phenyl -2- cyano butyramides | 精华制药集团南通有限公司 | 2018-09-28 | — | — | CN | claimed |
| US-7714020-B2 | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2010-05-11 | — | — | US | claimed |
| CN-100577663-C | Fused heterocyclic kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2010-01-06 | — | — | CN | claimed |
| JP-2009519467-A | — | — | 2009-05-14 | — | — | JP | claimed |
| EP-1990639-A1 | System and method for real-time diagnosis, treatment, and therapeutic drug monitoring | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2008-11-12 | — | — | EP | claimed |
| EP-1960775-A2 | SYSTEM AND METHOD FOR MONITORING HEALTH USING EXHALED BREATH | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2008-08-27 | — | — | EP | claimed |
| US-20070258894-A1 | System and Method for Real-Time Diagnosis, Treatment, and Therapeutic Drug Monitoring | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2007-11-08 | — | — | US | claimed |
| WO-2007089328-A2 | SYSTEM AND METHOD FOR MONITORING HEALTH USING EXHALED BREATH | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2007-08-09 | — | — | WO | claimed |
| US-20070167853-A1 | System and method for monitoring health using exhaled breath | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2007-07-19 | — | — | US | claimed |
| US-20060251649-A1 | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2006-11-09 | — | — | US | claimed |
| US-20050233459-A1 | Marker detection method and apparatus to monitor drug compliance | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2005-10-20 | — | — | US | claimed |
| US-20050054942-A1 | System and method for therapeutic drug monitoring | UNIVERSITY OF FLORIDA | 2005-03-10 | — | — | US | claimed |
| CN-1553899-A | Quinoline and quinazoline derivatives inhibiting autophosphorylation of hepatocyte growth factor receptor and pharmaceutical compositions containing these compounds | ������������ʽ���� | 2004-12-08 | — | — | CN | claimed |
| US-20250144013-A1 | Mycophenolate Oral Suspension | LIQMEDS WORLDWIDE LTD (GB) | 2025-05-08 | — | — | US | disclosed |
| US-20250070260-A1 | SLOT ELECTRODE STACK AND ELECTROCHEMICAL CELLS AND BATTERIES CONTAINING A SLOT ELECTRODE STACK | SEED INTELLECTUAL PROPERTY LAW GROUP LLP | 2025-02-27 | — | — | US | disclosed |
| US-12226526-B2 | Mycophenolate oral suspension | LIQMEDS WORLDWIDE LIMITED (GB) | 2025-02-18 | — | — | US | disclosed |
| WO-2004052350-A2 | METHOD OF TREATING MOVEMENT DISORDERS USING BARBITURIC ACID DERIVATIVES | TARO PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2004-06-24 | — | — | WO | disclosed |
| EP-1399146-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002098406-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
| WO-1989009209-A1 | PIPERIDINE RING MODIFIED PHENCYCLIDINE ANALOGS AS ANTICONVULSANTS | MARION LABORATORIES, INC. (US) | 1989-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060251649-A1 | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate | GRM2, GRIN2C, GRIN2A | ALOX5 1638/4885EPHX1 950/4885TRPM8 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.